Assertio Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Assertio Holdings, Inc.
Radiofrequencies from the incontinence-sensing devices may interfere with other medical equipment in a hospital setting.
Edwards Lifesciences CEO Mike Mussallem has a unique and long-standing perspective of what the medtech industry should be and do. In over two decades, he has built the structural heart disease and critical care monitoring company into one of the global medtech industry’s most effective innovators.
The company reported in October that it was reviewing its portfolio and would offer more details on its future plans in January. Wells Fargo analysts expect Baxter to split its fast-growing connected care business from its lower-margin hospital-based therapeutics products.
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
- Other Names / Subsidiaries
- Depomed, Inc.